Crizotinib: risk of cardiac failure

Cases of severe cardiac failure, some fatal, have been reported in patients treated with crizotinib (Xalkori), the MHRA has warned.

Crizotinib is licensed for treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer. | iStock

Monitoring requirements for crizotinib have been revised following a review conducted by the MHRA and other EU regulators. Healthcare professionals should be vigilant for signs and symptoms of cardiac failure, including dyspnoea, oedema and rapid weight gain from fluid retention. If such symptoms occur, appropriate measures such as dosing interruption, dose reduction or treatment discontinuation should be considered.

Further information
View Xalkori drug record
MHRA Drug Safety Update
Summary of Product Characteristics

Post-marketing reports

Forty cases of cardiac failure were reported during post-marketing surveillance of crizotinib to February 25, 2015. In most cases cardiac failure occurred within the first month of starting therapy. A fatal outcome was reported for 15 of these cases.

In seven cases, symptoms of cardiac failure resolved after discontinuation of crizotinib, three of which saw patients experience a recurrence of symptoms when crizotinib was re-introduced. Of the seven cases, three showed no pre-existing cardiac disorders, comorbid conditions or concurrent medications.

Cardiac failure is now listed as a common adverse effect in the Xalkori Summary of Product Characteristics.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Back of man's head suffering from alopecia

Alopecia drug to be available on the NHS

In an NHS first, NICE is recommending ritlecitinib...

Stressed male GP with hand on head